






1.	 Is	 risk-based	 selection	 to	 lung	 cancer	 screening	 the	 way	 forward?	 –	 Lessons	 from	 the	
PANCAN	study		
Lung	 cancer	 screening	 has	 the	 potential	 to	 save	 lives,	 though	 optimum	 methods	 for	
implementation	 in	 a	 cost-effective	manner	 are	 yet	 to	 be	 determined.	 The	 PANCAN	 study	
(Lancet	Oncol	2017;18:1523-31)	was	 the	 first	 screening	study	 that	used	a	 lung	cancer	 risk	




Lung	 Screening	 Trial	 (NLST,	 4%;	 p<0.001)	 and	 a	 higher	 proportion	 of	 early	 stage	 cancers	





from	 NLST	 and	 the	 Dutch-Belgian	 NELSON	 study	 and	 supports	 the	 use	 of	 less	 frequent	







To	 date,	 no	 agents	 have	 shown	 significant	 efficacy	 in	 the	 treatment	 of	 malignant	
mesothelioma	(MM),	though	early	in-vitro	and	animal	studies	have	shown	promising	results	
with	 recombinant	 TNF-related	 apoptosis	 inducing	 ligand	 (rTRAIL).	 Kolluri	 and	 colleagues	
(eLIFEn2018;7:e30224)	report	a	series	of	experiments	to	identify	novel	therapeutic	agents	in	
MM	and	elucidate	potential	mechanisms	of	action	to	demonstrate	biological	plausibility	of	
the	 association.	 In	 the	 first	 experiment,	 they	 treated	 15	mesothelioma	 cell	 lines	 with	 94	
anti-cancer	drugs	and	established	associations	between	specific	mutations	on	MM	cell	lines	
and	 drug	 response,	 the	 most	 significant	 of	 which	 was	 between	 loss	 of	 function	 (LOF)	
mutations	 of	 the	 tumour	 suppressor-	 BRCA	 associated	 protein-1	 (BAP1)	 and	 rTRAIL.	 Next	
the	 investigators	knocked	down	BAP1	expression	 in	wild	 type	BAP1	cell	 lines	and	 showed	
increased	 response	 to	 rTRAIL	 compared	 to	 an	 empty	 vector.	 Then,	 by	 introducing	 either	
wild-type	or	 various	mutant	 forms	of	BAP1	 into	 the	 cells	which	did	not	possess	 the	BAP1	
gene,	 they	 identified	 that	 BAP1	 modulates	 TRAIL	 sensitivity	 by	 associating	 with	 other	
protein	complexes	in	the	cell.	Finally,	they	confirmed	that	these	findings	were	reproducible	








3.	 Can	 serum	 LDH	 and	 full	 blood	 count	 determine	 lung	 cancer	 responsiveness	 to	
immunotherapy?	
In	patients	with	non-small-cell	lung	cancer	(NSCLC)	who	express	PDL-1,	immune	checkpoint	
inhibitor	 (IKI)	 treatment	 confers	 a	 survival	 advantage	 but	 currently	 there	 is	 a	 lack	 of	 a	
clinically	 accessible	 tool	 to	 identify	 patients	 likely	 to	 respond.	 Mezquita	 and	 colleagues	
(JAMA	 oncology:	 doi:10.1001/jamaoncol.2017.4771)	 used	 three	 retrospective	 datasets	 to	
examine	 the	 relationship	 between	 baseline	 plasma	 lactate	 dehydrogenase	 (LDH)	 and	
derived	neutrophil	to	lymphocyte	ratio	(dNLR;	absolute	neutrophil	count	/	[white	blood	cell	










potential	 role	of	 LIPI	 as	 a	 cost	 effective	 tool	 to	 aid	precision	medicine	 in	 IKI	 treatment	of	
NSCLC. 
	
4.	Does	osimertinib	 improve	 survival	 in	 treatment	naïve	EGFR	positive	non	 small	 cell	 lung	
cancer	compared	with	‘standard’	tyrosine	kinase	inhibitors?	
Tyrosine	kinase	inhibitors	(TKI)	have	become	standard	therapy	for	patients	with	non-small-
cell	 lung	 cancer	 (NSCLC)	 with	 EGFR	 mutations,	 extending	 survival	 in	 this	 patient	 group.	
However,	resistance	to	first	generation	TKIs	limits	duration	of	response.	The	FLAURA	study	
(NEJM	2018;378:113-25)	 used	 a	 phase	 III	 double	 blind	 design	 to	 compare	 osimertinib	 	 to	
standard	TKIs	 (gefitinib	or	erlotinib).	Participants	had	 locally	advanced	or	metastatic	EGFR	
mutation	 positive	 NSCLC	 and	 were	 thus	 eligible	 for	 first	 line	 TKI	 treatment.	 The	 study	
recruited	 556	 participants	 across	 132	 sites	 in	 29	 countries.	 The	 primary	 outcome	 of	
progression	 free	 survival	 (PFS)	was	 significantly	 longer	 in	 the	osimertinib	group	compared	
with	control	(18.9	vs.	10.2	months,	HR	0.46,	95%CI	0.37	to	0.57,p<0.001).	Positive	secondary	





action	of	 osimertinib	on	 the	 common	mechanism	of	 TKI	 resistance,	 the	 T790M	mutation.	
This	study	encouragingly	suggests	that	osimertinib	has	significant	clinical	benefits	over	first	
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